All PlansCoverageMedium impact
Measurement of Serum Antibodies to Selected Biologic Agents
Regence BlueShield·Family Medicine, Internal Medicine, Cardiology +5 more·Pharmacy
Effective date
Mar 1, 2026
We identified it
Jun 16, 2026
Summary
A new policy effective March 1, 2026 classifies genetic testing for methionine metabolism enzymes (CBS, MTHFR, MTR, MTRR, MMADHC genes) as investigational for all indications, meaning these tests will not be covered and patients will be financially responsible for costs.
Action Required
Before March 1, 2026: Billing team must update systems to flag genetic testing for CBS, MTHFR, MTR, MTRR, and MMADHC genes as non-covered/investigational. Providers must inform patients before ordering these tests that they will be financially responsible for costs. Update encounter forms and EMR templates with patient notification requirements.